[1] CHEN W, ZHENG R, BAADE P D, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
[2] GUAN Z Z, XU J M, LUO R C, et al.Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer:a randomized phase III ARTIST trial[J]. Chin J Cancer, 2011, 30(10):682-689.
[3] HURWITZ H, FEHRENBACHER L, NOVOTNY W, et al.Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer[J]. N Engl J Med, 2004, 350(23):2335-2342.
[4] BENNOUNA J, SASTRE J, ARNOLD D, et al.Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147):a randomised phase 3 trial[J]. Lancet Oncol, 2013, 14(1):29-37.
[5] VAN CUTSEM E, LENZ H J, KöHNE C H, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer[J]. J Clin Oncol, 2015, 33(7):692-700.
[6] HEINEMANN V, VON WEIKERSTHAL L F, DECKER T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3):a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2014, 15(10):1065-1075.
[7] VAN CUTSEM E, KöHNE C H, HITRE E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer[J]. N Engl J Med, 2009, 360(14):1408-1417.
[8] GROTHEY A, VAN CUTSEM E, SOBRERO A, et al.Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT):an international, multicentre, randomised, placebo-controlled, phase 3 trial[J]. Lancet, 2013, 381(9863):303-312.
[9] LI J, QIN S, XU R, et al.Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR):a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2015, 16(6):619-629.
[10] FUKUOKA S, HARA H, TAKAHASHI N, et al.Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer:An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)[J]. J Clin Oncol, 2020, 38(18):2053-2061.
[11] TABERNERO J, LENZ H J, SIENA S, et al.Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer:a retrospective, exploratory analysis of the CORRECT trial[J]. Lancet Oncol, 2015, 16(8):937-948.
[12] SHITARA K, YAMANAKA T, DENDA T, et al.REVERCE:a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients[J]. Ann Oncol, 2019, 30(2):259-265.
[13] LI J, QIN S, XU R H, et al.Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer:The FRESCO Randomized Clinical Trial[J]. Jama, 2018, 319(24):2486-2496.
[14] XU J, KIM T W, SHEN L, et al.Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer:The TERRA Study[J]. J Clin Oncol, 2018, 36(4):350-358. |
